ArticleResearch square2023

Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.

Shuying Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.